Read summaries of completed clinical trials, also called research studies.
Care guides can help you manage your health in the months and years after blood and marrow transplantAge19 years of age and olderNumber of Participants619Research GoalImprove Quality of LifeImprove SurvivalCare guides can help patients and caregivers understand long-term side effects of blood and marrow transplant (BMT), according to a new study.
- Age15 - 71 years oldNumber of Participants80Research GoalImprove SurvivalMany people don’t have a fully matched family or unrelated donor for a lifesaving blood or marrow transplant (BMT). Now, a new treatment may help more people have a safe mismatched BMT.
- AgeN/ANumber of ParticipantsN/AResearch GoalIncrease AccessSome people with Medicaid insurance face delays or other problems getting blood and marrow transplant (BMT) for sickle cell disease.
Lower income children with blood cancers are less likely to survive after blood and marrow transplantationAge0 - 18 years oldNumber of Participants3,749Research GoalImprove SurvivalChildren who have blood cancers are less likely to survive after transplant if their families are low-income compared to children from higher-income families, a new study found.
- Age0 - 17 years oldNumber of Participants2,569Research GoalImprove SurvivalResearchers created a tool to help doctors choose the best treatments for children with leukemia. The tool is called the Pediatric Disease Risk Index.
- Age0 - 74 years oldNumber of Participants127Research GoalImprove SurvivalScientists say a medicine called sirolimus can treat acute graft-versus-host disease (GVHD) and causes fewer side effects than older medicines.
- Age18 - 75 years oldNumber of Participants273Research GoalImprove SurvivalScientists found a new combination of medicines that helps prevent graft-versus-host disease (GVHD). The medicines also help people with blood cancers live longer.
- AgeN/ANumber of ParticipantsN/AResearch GoalImprove SurvivalA group of doctors who specialize in blood and marrow transplants, or BMT, now recommend CAR T-cell therapy in some cases.
- AgeN/ANumber of ParticipantsN/AResearch GoalImprove Quality of LifeStaff at blood and marrow transplant (BMT) centers want to help people return to work after transplant. But there is little guidance, according to research.
- AgeN/ANumber of ParticipantsN/AResearch GoalImprove Quality of LifeImprove SurvivalBlood and marrow transplant (BMT) is a highly complex treatment that can affect health for years afterward. Patients, caregivers and families receive a lot of information throughout BMT.
- AgeN/ANumber of ParticipantsN/AResearch GoalBe The Match Registry® overcomes COVID-19 challenges
- Age30-65 years oldNumber of Participants318Research GoalImprove SurvivalLargest study so far shows that most patients survive
- Age21-75 years oldNumber of Participants184Research GoalImprove Quality of LifeA small number of people regret having a blood or marrow transplant (BMT) within 6 to 12 months, research shows.
- Age0-12 months oldNumber of Participants2,498Research GoalImprove SurvivalMost studies of blood and marrow transplant (BMT) do not include babies younger than age 1.
- Age40-81 years oldNumber of Participants1,755Research GoalImprove SurvivalMore people with leukemia who had intense treatment just before blood or marrow transplant (BMT) got a bacterial infection, compared to people who had less intense treatment.
- Age18-60 years oldNumber of Participants2,271Research GoalImprove SurvivalVery high doses of irradiation before blood or marrow transplant (BMT) are only as helpful as standard high doses, according to a new study.
- Age19-80 years oldNumber of Participants274Research GoalImprove SurvivalResearch showing that cells can be carefully frozen and stored for blood and marrow transplant (BMT) will save lives during the COVID-19 pandemic and beyond.
- Age18-70 years oldNumber of Participants367Research GoalImprove SurvivalOnly 1 in 5 African Americans who need a blood or marrow transplant (BMT) can find a matched donor. A transplant from a half-matched or cord blood donor also can help, a new study shows. This may allow more African Americans to get a life-saving transplant.
- Age1-49 years oldNumber of Participants996Research GoalImprove SurvivalBlood or marrow transplant (BMT) can help people with severe sickle cell disease, but little was known about the best age for a person to get BMT or which type of donor is best.
- Age15 - 39 years oldNumber of Participants826Research GoalImprove Quality of LifeImprove SurvivalAbout 1 out of 4 teens or young adults who had blood or marrow transplants (BMT) to cure leukemia had at least 1 late side effect several years later.
- Age18 - 78 years oldNumber of Participants1,205Research GoalImprove SurvivalA haploidentical, or haplo, blood or marrow transplant (BMT) can help people with acute myeloid leukemia (AML), research shows. AML is a blood cancer that may be cured with BMT.
- AgeN/ANumber of ParticipantsN/AResearch GoalImprove SurvivalBlood and marrow transplant (BMT) is helpful for older people, but only 5-10% of older people who need BMT get this lifesaving treatment.
- Age50 - 75 years oldNumber of Participants384Research GoalImprove Quality of LifeImprove SurvivalAlthough BMT is the only known cure for MDS, many people aren’t aware of BMT or think that they’re too old to have one because of its side effects.
- Age18-70 years oldNumber of Participants370Research GoalImprove SurvivalAlthough blood and marrow transplant (BMT) can cure leukemia and lymphoma, some people can’t find a fully matched donor. And people with diverse ethnic backgrounds may have more difficulty finding a match.
- Age55-77 years oldNumber of Participants330Research GoalImprove Quality of LifeMemory problems might affect physical health during blood and marrow transplant (BMT), researchers say. Extra therapy may help.
- Age0-81 years oldNumber of Participants2,456Research GoalImprove SurvivalThe largest study of its kind found that unlicensed umbilical cord blood is safe and effective for umbilical cord blood transplant (UCBT).
For some people older than 50, transplant from young, matched donors is better than half-matched donorsAge50 - 75 years oldNumber of Participants822Research GoalImprove SurvivalIn this study, researchers learned that people older than 50 with acute leukemia live longer after a blood or marrow transplant (BMT) from a young, matched unrelated donor than from a half-matched family member.
- Age20 - 70 years oldNumber of Participants758Research GoalImprove SurvivalFor multiple myeloma, doctors recommend a single autologous blood or marrow transplant followed by only lenalidomide maintenance, instead of more intensive treatments. That’s news from a study that compared 3 treatments.
- AgeN/ANumber of ParticipantsN/AResearch GoalImprove SurvivalPeople who need a life-saving blood or marrow transplant (BMT) need to be especially careful to avoid COVID-19
- Age6-17 years oldNumber of Participants13Research GoalImprove Quality of LifeA small study found that blood or marrow transplant (BMT) may preserve intelligence in children with sickle cell disease.
- Age1 - 67 years oldNumber of Participants827Research GoalImprove SurvivalA new online calculator helps doctors decide when it’s safest to stop immune suppression medicines after blood or marrow transplant (BMT). This is important because, while these medicines protect against graftversus-host disease (GVHD), they also increase the risk of infections.
- Age0 - 88 years oldNumber of Participants511Research GoalImprove SurvivalA CAR T-cell therapy helps hard-to-treat cases of lymphoma and leukemia, according to a large study.
- Age18-38Number of Participants1,365Research GoalImprove Quality of LifeYoung adults who’ve had allogeneic blood and marrow transplant (BMT) are less likely to be employed than their peers.
- Age18-81 years oldNumber of Participants2,320Research GoalImprove SurvivalHalf-matched donors are acceptable if no match is found.
- Age18-91Number of Participants411Research GoalImprove SurvivalPeople with lymphoma should get a blood or marrow transplant (BMT) before trying newer chimeric antigen receptor T cell (CAR-T) therapy.
- Age0-21Number of Participants2,550Research GoalImprove SurvivalDoctors should not give certain antibiotics to children with leukemia during blood or marrow transplant (BMT).
- Age6+Number of Participants642Research GoalImprove SurvivalThe US Food and Drug Administration (FDA) recently approved abatacept as the first medicine to prevent acute graft-versus-host disease (GVHD).
- Age0-49 years oldNumber of Participants700Research GoalImprove SurvivalBoth help people who have acute leukemia but no matched donor.
- AgeN/ANumber of ParticipantsN/AResearch GoalImprove Quality of LifeMost children who have had blood or marrow transplant (BMT) may need to delay returning to school until they have been fully vaccinated for COVID-19.
- Age1-65 years oldNumber of Participants346Research GoalImprove SurvivalA recent clinical trial compared 2 new short-term treatments against 1 standard long-term treatment. The new treatments were not better than the standard, but all 3 treatments had the same proportion of patients who were alive without cancer relapse or significant CGVHD.
- Age1 - 48 years oldNumber of Participants1,425Research GoalImprove SurvivalBlood or marrow transplant (BMT) can cure sickle cell disease for some people. Now, doctors can predict which people will benefit most from BMT.
- AgeN/ANumber of Participants950Research GoalImprove SurvivalMost people who live for 2 years or longer after their blood or marrow transplant (BMT) are cured of their disease and can expect to live for many more years. That’s according to new research on BMT and sickle cell disease.
- Age18-70Number of Participants1,300Research GoalIncrease AccessThere are 3 sources for BMT: bone marrow, peripheral blood stem cells, and umbilical cord blood. These can come from fully matched or half-matched donors. A new study shows that for a person with leukemia or lymphoma, if a fully matched donor is not available, a halfmatched donor is better than umbilical cord blood.
- AgeAll agesNumber of Participants1,600Research GoalImprove Quality of LifeImprove SurvivalDoctors should team up to diagnose acute graft-versus-host disease, or aGVHD, more accurately. That’s according to new research.
aGVHD is one of the most common complications after blood or marrow transplant (BMT). AGVHD can start in the first 3 months after BMT but sometimes occurs later. About 90% (9 out of 10 patients) have symptoms that may indicate aGVHD after BMT.
- Age25-50yrsNumber of Participants14Research GoalImprove Quality of LifeImprove SurvivalBlood and marrow transplant (BMT) sometimes affects hormones and sexual health.
A group of doctors, researchers, and patient advocates published a review of scientific research. They said that BMT sometimes causes problems with hormones and sperm. Also, BMT may cause graft-versus-host disease (GVHD) and secondary cancers that impact the penis, testes, and scrotum.
- Age60<Number of Participants270Research GoalImprove Quality of LifeImprove SurvivalBlood and marrow transplant (BMT) can help people who have a rare blood cancer. T-cell prolymphocytic leukemia (T-PLL) is hard to treat— medicines alone typically are not enough for a long-term cure. New research shows that BMT is useful for some people who have this disease.
- Age22 - 44 years oldNumber of Participants33Research GoalImprove Quality of LifeModerate-intensity exercise, like biking, swimming, or fast-paced walking, can help people with sickle cell disease make more blood vessels in their muscles. That’s according to new research.